drugset / Trial / NCT05653427
A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to characterize the preliminary antitumor activity of amivantamab at the recommended dose in participants with previously systemically treated hepatocellular carcinoma (HCC)
Timeline
- Start
- 2022-12-08
- Primary completion
- 2023-10-10
- Completion
- 2023-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amivantamab | Monoclonal antibody | — | Intravenous |